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Abstract
Background: Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad
and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural
backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to
examine incidence and mortality patterns and trends in TT.
Methods: Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer
Registry (population-based cancer registry of TT) between 1995 and 2009 were analyzed. Age-standardized rates,
overall and by sex, ancestry, and geography, were reported.
Results: The highest incidence and mortality rates were observed for cancers related to reproductive organs in women,
namely, breast, cervical, and uterine cancers, and prostate, lung and colorectal cancers among men. Average incidence rates
were highest in areas covered by the Tobago Regional Health Authority (TRHA) (188 per 100,000), while average mortality
rates were highest in areas covered by the North West Regional Health Authority (108 per 100,000). Nationals of African
ancestry exhibited the highest rates of cancer incidence (243 per 100,000) and mortality (156 per 100,000) compared to their
counterparts who were of East Indian (incidence, 125 per 100,000; mortality, 66 per 100,000) or mixed ancestry (incidence,
119 per 100,000; mortality, 66 per 100,000).
Conclusions: Our findings highlight the need for national investment to improve the understanding of the epidemiology of
cancer in Trinidad and Tobago, and to ultimately guide much needed cancer prevention and control initiatives in the near
future.
Keywords: Trinidad and Tobago, Caribbean, Cancer incidence, Cancer mortality, Cancer surveillance, Cancer in populations
of African ancestry, Cancer in populations of Indian ancestry
Background
Cancer is the second leading cause of death in the
Caribbean and has created tremendous challenges for
healthcare services and expenditures throughout the
region [1]. The World Health Organization (WHO) pro-
jects that cancer incidence will increase by 58%, from
84,703 cases in 2015 to 133,937 cases in 2035, and
cancer mortality will increase by 67% during this period,
from 52,282 to 87,430 deaths [2]. Aging of the popula-
tion, improvements in healthcare and economic devel-
opment has led to a higher prevalence of lifestyle-related
risk factors for cancer, including reproductive behaviors,
dietary patterns, physical inactivity, obesity, and alcohol
and tobacco use. In addition, the prevalence of
cancer-associated viral infections (e.g., human papillo-
mavirus, human herpesvirus-8 (HHV8), human T-cell
lymphotropic virus-1 (HTLV-1), hepatitis B virus
(HBV)), may be higher among Caribbean populations
compared to United States (US) populations [3, 4].
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In the twin island nation of Trinidad and Tobago
(TT), cancer is a leading cause of death much like the
rest of the Caribbean [5]. These English-speaking islands
are unique in terms of their economy and ancestry. TT,
located off the northeastern edge of South America, is
one of the richest countries by gross domestic product
(GDP) per capita in the Americas and is classified as a
high-income economy by the World Bank [6]. This is
due to the nation’s industrialized economy, which in-
cludes petroleum, natural gas, chemical industries, and
food and beverage industries [7]. While TT is classified
as a developing country by the International Monetary
Fund (IMF) [8] and is a member of the United Nations
Conference of Small Island Developing States (SIDS) [9],
this nation faces major challenges in its efforts to
achieve developed nation status in sectors such as
healthcare [10]. TT’s estimated population is 1.4 million
[11] with an average life expectancy of 74.61 years [12].
From 1990 to 2010, the demographic profile of TT
underwent a transition marked by a declining fertility
rate, a decrease in the < 15 years age-group, and a doub-
ling of the > 60 years age-group [5]. While the Trinidad
population consists of diverse ancestral groups (includ-
ing African (31.76%), East Indian (37.01%), Mixed ances-
try (23.52%), Chinese, White, and Syrian/Lebanese (<
1%)), as well as religious groups (including Christian,
Muslim, and Hindu), the population in Tobago is pre-
dominantly of African ancestry (85.29%) and Christian
[11, 12]. These demographic patterns have resulted in
customs and traditions that have marked the sociocul-
tural development of the islands [13]. Hence, research
on the epidemiology and etiology of cancers in TT, in
relation to the environment, lifestyle and ancestry, is es-
sential for the success of cancer prevention and control
programs and policies.
The literature on the burden of cancer within TT remains
relatively barren. Previous studies of cancer in TT have re-
ported site-specific cancer incidence, mortality and survival
rates, including for breast, prostate, and gastric cancers [14–
19]. However, a comprehensive analysis of cancer incidence
and mortality has never been reported. Since 1994, the Dr.
Elizabeth Quamina Cancer Registry has served as the Na-
tional Cancer Registry of TT, using standard cancer registry
guidelines and statistical methods [20, 21].
Here, we present on cancer incidence and mortality
rates and trends in TT for the overall population, and by
sex, geography, ancestry, and age. This is the first epide-
miologic examination of cancer rates and trends across
all cancer sites in TT for the period 1995 to 2009.
Methods
We obtained retrospectively collected cancer surveil-
lance data (incidence and mortality) reported between
January 1, 1995 and December 31, 2009 to the National
Cancer Registry of TT, which represents all of the most
current and available data from the cancer registry. The
analytic dataset consisted of the 29,512 incident cancers
(pediatric and adult cases) reported during the study
period. The source of the registry records was previously
described [18]. In brief, the registry abstracts data from
private and public hospitals across Trinidad and Tobago
including all of the main cancer treatment centers. Ab-
stracted data included place of residence, age, sex, ances-
try, stage, grade and method of cancer detection. In the
registry data file, cancer histology was coded based on
WHO International Classification of Diseases for Oncol-
ogy (ICD-O) code C61.9. as supplied by the healthcare
institutions [22]. The boundaries for the geographic ana-
lysis by corporation and Regional Health Authority
(RHA) were previously described [18]. In brief, TT is di-
vided into fifteen governmental administrative corpora-
tions and five RHAs for healthcare delivery and
administration. Self-identification, medical records, and
to a lesser extent, imputation by binary logistic regres-
sion were used to determine ancestry [18].
Death certification and population data were obtained
from the Trinidad and Tobago Central Statistical Office
(CSO) 2000 and 2010 census. The population pyramids
for 2000 and 2011 were previously described [11, 12].
Populations estimates for the other study years were cal-
culated through interpolation using the “irregular points
of year” estimation method [20, 21]. The CSO collects
several population measures including age (single year of
age, 5- and 10-year age groups), ethnicity, and sex. From
these data points, we calculated the age-standardized in-
cidence and mortality rates (per 100,000 TT population)
by age (10-year), sex, geography, ancestry, and individual
years based on the 1960 world-standardized population
[23, 24]. This methodology was selected for ease of com-
parison with the International Agency for Research on
Cancer (IARC) data which uses the same
standardization. The TT case fatality rate was calculated
by dividing the number of cancer deaths over the study
period by the number of incident cases and then multi-
plying the resultant ratio by 100 to yield a percentage.
For the period 1995–2007, the average time between
cancer incidence and cancer death was calculated by tak-
ing the average length of the time from the year of inci-
dence to the year of death for the 15,279 cancer deaths
recorded during the same time period. For the same
time period, the mean survival time (among cancer cases
reported in the registry as still living at last contact,
N = 10,087) was calculated by taking the average of
the time from incidence to date of last contact. The
geospatial maps were rendered in the R computing
environment [25] and Statistical Package of Social
Science (SPSS) V.20 (IBM Corporation, Valhalla, NY)
was used for analyses.
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Results
Cancer incidence and mortality rates among men and
women
The number and percentage of cancer cases and deaths,
along with age-standardized cancer incidence and mor-
tality rates are shown in Table 1. Between 1995 and
2009, there were a total of 29,512 incident primary can-
cers and 18,216 cancer deaths in TT, with an overall
case-fatality rate of 61.7%. For this time period, the aver-
age length of time between diagnosis and death was
1 year (range: less than 1 year to 40 years) and the aver-
age survival time among living cases was 1.1 year (range:
less than 1 year to 14 years). Several basic metrics of
data quality from the registry are provided (Add-
itional file 1: Table S1). Of note, the percent of cases reg-
istered only on the basis of the death certificate only
(DCO) fluctuated from 12.12% in 1995 to 27.63% in
2000 to 10.48% in 2005 and then to 6.32% in 2009. The
average over the study period was 18.44%.
Overall, cancer incidence and mortality rates were 13.4
and 22.3% higher, respectively, among men than women.
Cancer incidence and mortality trends by sex in TT are
shown in Fig. 1. The overall age-standardized cancer in-
cidence rate among TT men was 159.7 per 100,000,
while the overall mortality rate was 103.8 per 100,000.
The most commonly diagnosed cancers among men
were prostate (64.0 per 100,000), lung and bronchus
(15.9 per 100,000), colon (11.6 per 100,000), hematologic
(11.4 per 100,000) and stomach (6.5 per 100,000). Simi-
larly, the cancers with the highest mortality rates among
men were prostate (37.5 per 100,000), lung and bron-
chus (12.7 per 100,000), hematologic (8.2 per 100,000),
colon (7.6 per 100,000) and stomach cancer (5.3 per
100,000). Among TT women, the overall
age-standardized cancer incidence rate was 146.3 per
100,000, while the overall mortality rate was 81.5 per
100,000. The most commonly diagnosed cancers among
women were breast (46.6 per 100,000), cervix uteri (18.1
per 100,000), corpus uteri (13.4 per 100,000),
hematologic (9.1 per 100,000), colon (9.0 per 100,000)
and ovarian cancer (8.9 per 100,000). The cancers with
the highest mortality were breast (18.4 per 100,000), cer-
vix uteri (9.7 per 100,000), corpus uteri (6.4 per
100,000), hematologic (6.5 per 100,000) and ovarian (5.8
per 100,000) (Table 1A, B).
Cancer incidence and mortality rates by geography
The geographical area of residence corresponded with
Ministry of Health RHAs (Fig. 2). There are five RHAs
in TT – North West Regional Health Authority
(NWRHA); North Central Regional Health Authority
(NCRHA); South West Regional Health Authority
(SWRHA); Eastern Regional Health Authority (ERHA);
and Tobago Regional Health Authority (TRHA) –
responsible for direct provision of healthcare services in
their respective catchment area [18]. As shown in Fig. 2,
age-standardized cancer incidence and mortality rates
varied by RHA. Average incidence rates were highest in
areas covered by the TRHA (188 per 100,000), followed
by NWRHA (173 per 100,000), and NCRHA (153 per
100,000), compared to ERHA (139 per 100,000) and
SWRHA (131 per 100,000). Overall, average mortality
rates were highest in areas covered by NWHRA (108 per
100,000), followed by NCRHA and TRHA, (94 and 91
per 100,000, respectively). The NWRHA covers the area
that includes the capital city of Port-of-Spain, which had
the highest overall age-standardized cancer incidence
(238 per 100,000) and mortality (151 per 100,000). Cor-
porations within the SWRHA catchment area, Penal and
Debe (110 per 100,000) and Couva, Tabaquite, and Tal-
paro (119 per 100,000) had among the lowest overall
cancer incidence rates. Penal and Debe had the lowest
cancer mortality (59 per 100,000).
Cancer incidence and mortality by ancestry
The highest cancer incidence (243 per 100,000) and
mortality (156 per 100,000) rates were observed among
individuals of African ancestry compared to Indian or
mixed ancestry (Fig. 3). Cancer incidence and mortality
rates by sex, ancestry, and age in TT are shown in Fig. 4.
The highest burden of cancer for both men and women
were observed among those ≥45 years. Among TT men,
cancers with the highest incidence and mortality (pros-
tate, colon, hematologic and stomach cancers) were ob-
served among those 65–74 years (Fig. 4a-e). However,
the highest lung cancer rates were observed among
those aged 55–64 years (Fig. 4b). Among TT women,
the highest breast and cervical cancer incidence and
mortality rates were observed among those 45–54 years
(Fig. 4f-j). Women 55–64 years experienced the highest
corpus uteri incidence, while colon cancer and ovarian
cancer occurred most frequently among women 65–
74 years (Fig. 4h-j). The highest mortality rates for cor-
pus uteri cancer were observed among women 55–
64 years, while the highest mortality rates for colon and
ovarian cancers were observed for women 65–74 years
(Fig. 4h-j). Incidence and mortality data for those under
24 is provided (Additional file 2: Table S2).
Stage distribution of selected cancers
Figure 5 shows the distribution of stage at diagnosis among
the leading cancers by sex and ancestry. Most prostate can-
cers were diagnosed at localized stage (African 42%, Indian
46%, and mixed ancestry 39%). More than 15% of lung and
bronchus (African 21%, Indian 19%, and mixed ancestry
33%) and stomach cancers (African 18%, Indian 19%, and
mixed ancestry 28%) occurred in the distant stage. Less
than 15% of breast (African 10%, Indian 6%, and mixed
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Table 1 Counts, percentages, and age-standardized incidence (A) and mortality (B) rates per 100,000 for adult and pediatric cancers,
Trinidad and Tobago, 1995–2009
(A) Incidence
Cancer site
Both sexes Men Women






Bones & joints C40, C41 156 (0.8%) 0.8 95 (0.6%) 0.9 61 (0.4%) 0.6
Brain & other nervous system C70 – C72 370 (1.9%) 2.0 222 (1.5%) 2.5 148 (1.0%) 1.6
Breast C50 4685
(24.6%)
46.6# 72 (0.5%) 0.8 4613
(31.6%)
46.6







Colon C18 2023 (10.6%) 10.3 1084 (7.3%) 11.6 939 (6.4%) 9.0
Liver C22 432 (2.3%) 2.2 242 (1.6%) 2.6 190 (1.3%) 1.8
Pancreas C25 902 (4.7%) 4.6 489 (3.3%) 5.3 413 (2.8%) 3.9
Rectum C20 620 (3.3%) 3.2 358 (2.4%) 3.9 262 (1.8%) 2.6
Stomach C16 999 (5.2%) 5.0 607 (4.1%) 6.5 392 (2.7%) 3.7
Othera C15, 17, 19, 21, 23, 24,
26
991 (5.2%) 4.2 560 (3.7%) 5.0 431 (3.0%) 3.5
Endocrine system C73 – C75 241 (1.3%) 1.2 73 (0.5%) 0.8 168 (1.2%) 1.6
Eye & orbit C69 38 (0.2%) 0.3 25 (0.2%) 0.3 13 (0.1%) 0.2
Hematologicb C42, C77 1949
(10.2%)
10.3 1062 (7.1%) 11.4 887 (6.1%) 9.1
Oral cavity & pharynx C00 – C14 744 (3.9%) 3.9 532 (3.6%) 5.8 212 (1.5%) 2.1





Penis C60 – – 87 (0.6%) 0.8 – –
Prostate C61 – – 6064 (40.6%) 64.0 – –
Testis C62 – – 79 (0.5%) 0.7 – –
Other male genitals C63 – – 3 (0.0%) 0.0 – –
Cervix uteri C53 – – – – 1812 (12.4%) 18.1
Corpus uteri C54 – – – – 1275 (8.7%) 13.4
Ovary C56 – – – – 885 (6.1%) 8.9
Vagina C52 – – – – 81 (0.6%) 0.6
Vulva C51 – – – – 59 (0.4%) 0.6
Other female genitals C55, C58, C63 – – – – 109 (0.7%) 0.8




20.7 501 (3.4%) 4.9
Larynx C32 343 (1.8%) 1.8 321 (2.1%) 3.5 22 (0.2%) 0.2
Lung bronchus C34 1857 (9.7%) 9.7 1460 (9.8%) 15.9 397 (2.7%) 3.9
Otherc C30, 31, 33, 37, 38 208 (1.1%) 0.9 126 (0.8%) 1.2 82 (0.6%) 0.7
Skin (excluding basal &
squamous)
C44 398 (2.1%) 2.0 234 (1.6%) 2.5 164 (1.1%) 1.6
Soft tissue (including heart) C47 – C49 274 (1.4%) 1.4 151 (1.0%) 1.6 123 (0.8%) 1.3
Urinary system C64 – C68 682 (3.6%) 3.6 443 (3.0%) 4.9 239 (1.6%) 2.5
Ill-defined & unknown C76, C80 1146 (6.0%) 5.9 547 (3.7%) 5.9 599 (4.1%) 5.9










Bones & joints C40, C41 92 (0.8%) 0.5 56 (0.6%) 0.5 36 (0.4%) 0.4
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Table 1 Counts, percentages, and age-standardized incidence (A) and mortality (B) rates per 100,000 for adult and pediatric cancers,
Trinidad and Tobago, 1995–2009 (Continued)
(A) Incidence
Cancer site
Both sexes Men Women






Brain & other nervous system C70 – C72 206 (1.1%) 1.1 117 (1.2%) 1.3 89 (1.1%) 0.9
Breast C50 1990
(16.5%)
19.2# 35 (0.4%) 0.4 1955
(23.5%)
19.2







Colon C18 1331 (11.0%) 6.6 719 (7.3%) 7.6 612 (7.4%) 5.7
Liver C22 400 (3.3%) 2.0 223 (2.3%) 2.4 177 (2.1%) 1.6
Pancreas C25 796 (6.6%) 4.0 436 (4.4%) 4.7 360 (4.3%) 3.4
Rectum C20 338 (2.8%) 1.7 199 (2.0%) 2.1 139 (1.7%) 1.3
Stomach C16 841 (7.0%) 4.2 503 (5.1%) 5.3 338 (4.1%) 3.2
Othera C15, 17, 19, 21, 23, 24,
26
753 (6.2%) 3.8 422 (4.3%) 4.5 331 (4.0%) 3.2
Endocrine system C73 – C75 125 (1.0%) 0.6 42 (0.4%) 0.5 83 (1.0%) 0.8
Eye & orbit C69 11 (0.1%) 0.1 6 (0.1%) 0.1 5 (0.1%) 0.1
Hematologicb C42, C77 1407
(11.6%)
7.3 769 (7.8%) 8.2 638 (7.7%) 6.5
Oral cavity & pharynx C00 – C14 446 (3.7%) 2.3 330 (3.3%) 3.6 116 (1.4%) 1.2





Penis C60 – – 37 (0.4%) 0.4 – –
Prostate C61 – – 3704 (37.4%) 37.5 – –
Testis C62 – – 29 (0.3%) 0.3 – –
Other male genitals C63 – – 2 (0.0%) 0.0 – –
Cervix uteri C53 – – – – 974 (11.7%) 9.7
Corpus uteri C54 – – – – 632 (7.6%) 6.4
Ovary C56 – – – – 582 (7.0%) 5.8
Vagina C52 – – – – 42 (0.5%) 0.4
Vulva C51 – – – – 38 (0.5%) 0.4
Other female genitals C55, C58, C63 – – – – 87 (1.0%) 0.8




15.2 368 (4.4%) 3.6
Larynx C32 184 (1.5%) 0.9 174 (1.8%) 1.8 10 (0.1%) 0.1
Lung bronchus C34 1477 (12.2%) 7.7 1162 (11.7%) 12.7 315 (3.8%) 3.1
Otherc C30, 31, 33, 37, 38 116 (1.0%) 0.6 73 (0.7%) 0.7 43 (0.5%) 0.4
Skin (excluding basal &
squamous)
C44 141 (1.2%) 0.7 83 (0.8%) 0.9 58 (0.7%) 0.5
Soft tissue (including heart) C47 – C49 140 (1.2%) 0.8 83 (0.8%) 0.9 57 (0.7%) 0.6
Urinary system C64 – C68 419 (3.5%) 2.1 276 (2.8%) 3.0 143 (1.7%) 1.4
Ill defined & unknown C76, C80 875 (7.2%) 4.4 416 (4.2%) 4.4 459 (5.5%) 4.4
TOTALd 12,088 61.5 9896 103.8 8320 81.5
NOTE: Percentages may not sum to 100% due to rounding. Information refering to major organ systems are bolded
aAnus, anal canal, bile tract, esophagus, gall bladder, gastrointestinal, rectosigmoid junction, small intestine
bMyeloma, lymphoma, leukemia
cAccessory sinus, ear/nose, heart, pleura, respiratory tract, thymus, trachea
dExcludes genital cancer
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ancestry 8%) and cervix uteri cancers (African 10%, Indian
6%, and mixed ancestry 8%) occurred in the distant stage.
More than 30% of all ovarian cancers (African 36%, Indian
27%, and mixed ancestry 31%) occurred in the distant stage.
Strikingly, across all sites, there was a high percentage (12–
57%) of cancers with unknown stage.
Discussion
This is the first epidemiologic study to examine TT can-
cer rates and trends across all cancer sites, by age, ances-
try, geography and sex, with a focus on the cancers with
highest incidence rates. We found that incident cases of
prostate, lung, colon, stomach, and hematologic cancers
were most common among men, while among women,
the cancers with the highest incidence were breast,
cervical, endometrial, colon, and ovarian. Overall, the in-
cidence rates were highest in Tobago and the area cov-
ered by the NWRHA (which contains the capital city of
Port-of-Spain), while cancer mortality was highest in
NWRHA. The highest incidence and mortality rates
were observed among adults aged ≥45 years. Except cer-
vical and breast cancers, most cancers had a significant
proportion of cases (> 10%) diagnosed at distant stage
and all cancers except breast had > 20% with unknown
stage. TT nationals of African ancestry had the highest
incidence and mortality rates. The high overall
case-fatality rate reflects the need for improved strat-
egies to reduce cancer mortality in TT.
Evidence suggests that many of the most prevalent
cancers among men and women in TT are likely
a b
c d
Fig. 1 Trends in rates for selected cancers by sex, Trinidad and Tobago, 1995 to 2009. Rates are age adjusted to the 1960 world standard
population. a, b incidence and mortality cancer rates for men and (c, d) incidence and mortality cancer rates for women




Fig. 2 Geospatial maps of cancer incidence and mortality rates in Trinidad and Tobago 1995–2009: (Top panel, left to right) Age-standardized
incidence rates for all (a) Regional Health Authorities and (b) Corporations, and age-standardized mortality rates for all (c) Regional Health Authorities
and (d) Corporations. Rates are age adjusted to the 1960 world standard population. H, Hospital
Fig. 3 Overall cancer incidence and mortality rates in Trinidad and Tobago by ancestry, 1995–2009. Rates are age adjusted to the 1960 world
standard population





Fig. 4 Age-standardized incidence and mortality rates for the leading cancer sites by sex (a-e, male; f-j, female), ancestry (purple, African ancestry;
orange, Indian ancestry; gray, Mixed ancestry), and age groups, Trinidad and Tobago, 1995–2009. All bars are uniformly scaled. Data for persons
under 24 are presented in Additional file 2: Table S2
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attributable to preventable lifestyle factors (e.g., associ-
ated with the “westernized lifestyle” of developed coun-
tries). Tobacco use, obesity, pathogens, physical
inactivity, diet, and alcohol are among the known life-
style factors associated with increased cancer incidence
[26–29]. A recent study in TT reported that the current
prevalence of tobacco use among men (33.5%) is signifi-
cantly higher than among women (9.4%), which may
contribute to the higher rate of lung cancer among men
[30]. Additionally, the study found that the overall mean
body mass index (BMI) for women and men in TT was
27.4 kg/m2 and 25.6 kg/m2, respectively, and that >
55.7% of the population was overweight or obese (BMI
≥25) [30]. A recent IARC working group comprehensive
review of multiple datasets, concluded that excess body
fat causes cancer in multiple anatomical sites, including
those identified in this study as placing the highest bur-
den in TT [31, 32]. Numerous studies have reported the
causal relationship between physical inactivity and can-
cer [33–35], and while the amount of total physical ac-
tivity (PA) required to lower the risk of specific cancers
in a dose-response fashion has not been established, the
WHO recommends at least 600 metabolic equivalents of
task (MET) minutes/week for health benefits [36]. Strik-
ingly, a recent study in TT reported that the median PA
approximated 300.30 (MET minutes/week) (median,
149.1 MET minutes/week) [30]. Focused cancer preven-
tion initiatives in TT targeting obesity reduction and an
increase in PA might have value in reducing the risk of
cancer.
The TT population of African ancestry suffers a higher
cancer burden across all cancer sites. This is similar to
studies reporting that members of the African diaspora
suffer a disproportionate cancer burden compared to
other groups [37, 38]. Interestingly, we found that in
Tobago, with its relatively homogeneous African ances-
try population, there was a higher overall cancer inci-
dence rate (187.7 per 100,000), driven primarily by the
incidence rates of breast and prostate cancers. Surpris-
ingly, while the incidence rates are high, mortality rates
are relatively low (91.3 per 100,000). Further exploration
is needed to evaluate the causes of the excess cancer
burden, which may include genetic variation, tumor
biology, and additional factors that have been understud-
ied in the TT population. The contribution of tumor
biology, genomics, comorbidities and patterns of care to
the higher cancer burden and the observed disparities is
not clear and warrant further exploration.
There are no national cancer screening programs in TT.
However, the results from a population-based prostate
cancer screening in Tobago between September 1997 and
June 2001 are particularly worth noting. Here screening
for prostate cancer using serum prostate-specific antigen
(PSA) and digital rectal exam (DRE) revealed a very high
prevalence of clinically-detected prostate cancer [39].
While it is true that increased prostate cancer screening
leads to higher incidence, data support the hypothesis that
populations of African descent share genetic and/or life-
style factors that underlie an elevated prostate cancer risk
[40, 41]. A recent study compared the effect of birthplace
Fig. 5 Stage distribution of selected cancers by sex, Trinidad and Tobago, 1995–2009. Stage categories may not sum to 100% because of rounding
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on prostate cancer risk comparing US-born men and men
from two Caribbean countries (Guyana and TT) [19]. This
study found that Caribbean-born men were diagnosed at
an older age and had worse 5-year survival than US-born
men, although among Caribbean-born men who immi-
grated to the US, 5-year survival was similar to that of
US-born African American men [19]. A similar study of
breast cancer reported lower survival among Caribbean
women of African ancestry living in the Caribbean com-
pared to those who migrated to the US, compared to
US-born African American women [15]. This gap could
be due to the intersection of screening, health literacy,
tumor biology, genomics, and patterns of care issues [42].
This study has certain limitations, perhaps the greatest
of which was the limited quality of cancer surveillance
data currently available on the TT population. For ex-
ample, large proportions of data on cancer stage were
missing and molecular subtype for breast cancer, for ex-
ample was not reported, which precludes interpretation
of some of the study’s findings. There are issues related
to the data validity that can be addressed by an increase
in the quality of the data collected and improved steps
to have its data included in Cancer Incidence in Five
Continents. While the average DCO cases of 18.44% falls
below the threshold set by IARC for inclusion in Cancer
Incidence in Five Continents [43], it still reflects a need
for the TT cancer registry to improve data validity. Fluc-
tuations in data quality over the study period might have
impacted some of the trends we report. This further
highlights the need to strengthen the capacity of the
registry. Another limitation was the inability to access
and examine cancer screening data, which would be an
important consideration in terms of the mortality dispar-
ities reported herein. It is plausible that disparities in
cancer mortality were associated with disparities in ac-
cess and utilization of cancer screening tests, because of
differences in socioeconomic status, geography and/or
other factors. Furthermore, under the equal access to
care model in TT, initiation and receipt of optimal can-
cer treatment, as well as cancer care overall, may be
dependent upon a patient’s place of residence, and there-
fore related to differences in resource allocation by
RHAs. Another limitation was the lack of information
on where patients sought cancer care (i.e., within the
catchment area of their assigned RHA or elsewhere).
Cancer surveillance data collected in TT is not routinely
linked to tumor clinicopathological data leading to com-
promised data accuracy, utility and quality. Additionally,
TT does not have electronic health records, further lim-
iting the availability for this detailed cancer data. Similar
to National Cancer Institute’s Surveillance, Epidemiology
and End Results (SEER) registries, data on behavioral
characteristics of cancer cases are not included in the
TT cancer registry. This highlights the need for
improved cancer surveillance that can accurately inform
and support cancer prevention and control initiatives
[44]. Despite these limitations, this study highlights the
need for national strategic investment in cancer epi-
demiology, prevention and control.
Conclusion
In conclusion, the findings of this study demonstrate that
in TT, the highest incidence and mortality rates were ob-
served for cancers related to reproductive organs in
women, and prostate, lung and colorectal cancers among
men, with differences observed by geography and ances-
try. In developed countries, prostate and breast cancer
rates are decreasing, unlike in TT, where the rates are in-
creasing. Thus, the findings reported herein highlight the
need for national investment to improve the understand-
ing of the epidemiology of cancer in Trinidad and Tobago,
and to ultimately guide much needed cancer prevention
and control initiatives in the near future. Cancer preven-
tion efforts should be strategically increased, particularly
among those cancers that are attributable to lifestyle
choices. The high proportion of cancers diagnosed at dis-
tant and unknown stages, also highlights the need for im-
provements in cancer screening and treatment initiatives
in TT. Considering the high burden of cancer in TT, we
expect that findings from this study will inform future pol-
icies, particularly related to resource allocation across the
cancer care continuum in TT. Additionally, it is clear that
capacity-building within the cancer registry (e.g., to
mandate standardized data collection and routine molecu-
lar subtyping of tumors) is essential for improved cancer
surveillance. This will undoubtedly improve the quality of
data available for future research and will play an instru-
mental role in improving cancer care in TT.
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